Market Place
Sourcing Support
KAHR and Cancer Focus Fund Begin Dosing in Phase 1b Trial of DSP107
17 Feb 2022 //
PRNEWSWIRE
An Israeli biotech is looking to make its name in the jam-packed CD47 space
16 Jun 2021 //
ENDPTS
Kahr reels in $47M to fund CD47 trial, work on TIGIT prospect
16 Jun 2021 //
FIERCEBIOTECH
KAHR Announces $46.5 Million Financing for Immunotherapeutic Pipeline
16 Jun 2021 //
PRNEWSWIRE
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.